Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
A consistent upward trajectory is observed across all profitability metrics from 2018 to 2022, characterized by a significant acceleration in financial performance between the 2020 and 2021 fiscal years. While growth was incremental during the first three years of the period, the subsequent two years demonstrate a substantial expansion in both operating and net earnings.
- EBITDA Growth Trends
- Earnings before interest, tax, depreciation and amortization grew steadily from US$ 1,898 million in 2018 to US$ 2,083 million in 2020. A sharp inflection point occurred in 2021, with EBITDA rising to US$ 2,773 million, and further increasing to US$ 2,897 million by the end of 2022. This represents a cumulative increase of approximately 52.6% over the five-year window.
- Operating Profitability (EBIT)
- EBIT mirrored the EBITDA trend but experienced a more pronounced surge in the later years. Operating income remained relatively flat between 2018 and 2020, moving from US$ 757 million to US$ 796 million. However, EBIT nearly doubled in 2021 to US$ 1,509 million and continued its climb to US$ 1,767 million in 2022, indicating improved operational efficiency and scaling.
- Net Income and EBT Performance
- Earnings before tax (EBT) and net income exhibited greater volatility in the early period, with net income declining from US$ 259 million in 2018 to US$ 191 million in 2019. Following this dip, a rapid growth phase began in 2021, where net income surged to US$ 966 million, eventually reaching US$ 1,091 million in 2022. The growth rate of net income significantly outpaced the growth rate of EBITDA during the 2020-2022 interval.
- Analysis of Depreciation and Amortization
- A substantial and persistent gap is observed between EBITDA and EBIT, signifying high non-cash charges. In 2022, the difference between EBITDA (US$ 2,897 million) and EBIT (US$ 1,767 million) was US$ 1,130 million. The magnitude of this spread suggests a capital-intensive operational structure or the presence of significant intangible asset amortization.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Enterprise Value to EBITDA Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 44,519) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 2,897) |
| Valuation Ratio | |
| EV/EBITDA | 15.37 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| AbbVie Inc. | 32.43 |
| Amgen Inc. | 17.42 |
| Bristol-Myers Squibb Co. | 10.74 |
| Danaher Corp. | 24.92 |
| Eli Lilly & Co. | 46.09 |
| Gilead Sciences Inc. | 16.57 |
| Johnson & Johnson | 16.65 |
| Merck & Co. Inc. | 14.06 |
| Pfizer Inc. | 13.22 |
| Regeneron Pharmaceuticals Inc. | 15.04 |
| Thermo Fisher Scientific Inc. | 24.43 |
| Vertex Pharmaceuticals Inc. | 26.93 |
| EV/EBITDA, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 22.53 |
| EV/EBITDA, Industry | |
| Health Care | 20.66 |
Based on: 10-K (reporting date: 2022-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 53,832) | 55,061) | 47,884) | 42,823) | 38,267) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 2,897) | 2,773) | 2,083) | 1,992) | 1,898) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | 18.58 | 19.86 | 22.99 | 21.50 | 20.16 | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| AbbVie Inc. | 13.31 | 13.44 | — | — | — | |
| Amgen Inc. | 12.97 | 13.22 | — | — | — | |
| Bristol-Myers Squibb Co. | 9.46 | 8.65 | — | — | — | |
| Danaher Corp. | 18.42 | 21.05 | — | — | — | |
| Eli Lilly & Co. | 37.76 | 29.86 | — | — | — | |
| Gilead Sciences Inc. | 13.89 | 8.57 | — | — | — | |
| Johnson & Johnson | 14.78 | 14.47 | — | — | — | |
| Merck & Co. Inc. | 13.91 | 12.18 | — | — | — | |
| Pfizer Inc. | 6.12 | 8.64 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 15.27 | 6.68 | — | — | — | |
| Thermo Fisher Scientific Inc. | 20.25 | 20.21 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 14.91 | 18.92 | — | — | — | |
| EV/EBITDA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 13.58 | 13.16 | — | — | — | |
| EV/EBITDA, Industry | ||||||
| Health Care | 14.00 | 14.33 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 53,832 ÷ 2,897 = 18.58
4 Click competitor name to see calculations.
Between 2018 and 2022, a divergent trend is observed between the growth of Enterprise Value (EV) and Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA), which directly influenced the EV/EBITDA valuation multiple.
- Enterprise Value Trend
- Enterprise Value experienced a consistent upward trajectory from 2018 to 2021, rising from 38,267 million USD to a peak of 55,061 million USD. A slight contraction occurred in 2022, with the value decreasing to 53,832 million USD, though it remained significantly higher than the 2018 baseline.
- EBITDA Growth
- Operational profitability demonstrated steady and uninterrupted growth throughout the five-year period. EBITDA increased annually, moving from 1,898 million USD in 2018 to 2,897 million USD in 2022, reflecting a sustained improvement in earnings capacity.
- EV/EBITDA Ratio Analysis
- The valuation multiple exhibited a non-linear trend. The ratio climbed from 20.16 in 2018 to a peak of 22.99 in 2020, indicating that Enterprise Value grew at a faster rate than EBITDA during the initial three years. However, a reversal occurred in 2021 and 2022, with the ratio descending to 19.86 and 18.58, respectively. This downward trend in the latter two years suggests that EBITDA growth began to outpace the growth of Enterprise Value, leading to a relative compression in the valuation multiple.
The overall analysis indicates that while the absolute scale of both Enterprise Value and EBITDA increased over the period, the company ended the sequence with a lower valuation multiple than it started with in 2018, suggesting a more earnings-supported valuation by the end of 2022.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?